SMOFKABIVEN PERIPHERAL EMULSION FOR INFUSION

2. What you need to know before you start using SMOFKABIVEN PERIPHERAL

Do not use SmofKabiven Peripheral:

-if you are allergic (hypersensitive) to the active substances or to any of the other components of this medicine (listed in section 6).

-if you are allergic to fish or eggs

-if you are allergic to peanuts or soy, you should not use this product. SmofKabiven Peripheral contains soybean oil.

-if you have too much fat in your blood (hyperlipidemia)

-if you have severe liver impairment

-if you have blood coagulation problems (coagulation disorders)

-if your body has problems using amino acids

-if you have severe kidney disease without the possibility of dialysis

-if you are in acute shock

-if you have too much sugar in your blood (hyperglycemia) that is not controlled

-if you have high levels of salts (electrolytes) in your blood (serum) included in SmofKabiven Peripheral

-if you have fluid in your lungs (acute pulmonary edema)

-if you have too much fluid in your body (overhydration)

-if you have heart failure that is not being treated

-if you have a defect in your blood coagulation system (hemophagocytic syndrome)

-if you are in an unstable situation, such as after severe trauma, uncontrolled diabetes mellitus, acute heart attack, stroke, blood clot, metabolic acidosis (a condition that leads to too much acid in your blood), severe infection (sepsis), coma, and if you do not have enough fluid in your body (hypotonic dehydration).

-in children under 2 years of age

Warnings and precautions

Talk to your doctor before starting to use SmofKabiven Peripheral if you have:

-kidney problems

-diabetes mellitus

-pancreatitis (inflammation of the pancreas)

-liver problems

-hypothyroidism (thyroid problems)

-sepsis (severe infection)

If during the infusion you experience fever, rash, swelling, difficulty breathing, chills, sweating, nausea, or vomiting, inform your healthcare professional immediately, as these symptoms could be caused by an allergic reaction or because you are receiving too much of the medicine.

Your doctor will need to regularly check your blood to monitor liver function tests and other values.

Children and adolescents

SmofKabiven Peripheral is not intended for newborns or children under 2 years of age. SmofKabiven Peripheral can be administered to children from 2 to 16/18 years of age.

Using SmofKabiven Peripheral with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines, including those bought without a prescription.

Pregnancy and breastfeeding

There is no information on the use of SmofKabiven Peripheral during pregnancy or breastfeeding. Therefore, SmofKabiven Peripheral should only be administered to pregnant or breastfeeding women if the doctor considers it necessary. The use of SmofKabiven Peripheral may be considered during pregnancy and breastfeeding if your doctor advises it.

Talk to your doctor or pharmacist before using any medicine.

Driving and using machines

This is not relevant, as this medicine is administered in a hospital.

3. How to use SMOFKABIVEN PERIPHERAL

Follow exactly the administration instructions for this medicine given by your doctor. If you are unsure, consult your doctor again.

Your doctor will decide the dose for you individually, depending on your body weight and situation. SmofKabiven Peripheral will be administered to you by a healthcare professional.

If you use more SMOFKABIVEN PERIPHERAL than you should:

It is very unlikely that you will receive too much of the medicine, as SmofKabiven Peripheral will be administered by a healthcare professional.

4. Possible side effects

Like all medicines, SmofKabiven Peripheral can cause side effects, although not everybody gets them.

Common(may affect up to 1 in 10 people): a slight increase in body temperature. Inflammation in superficial peripheral veins that are in contact with the injection site.

Uncommon(may affect up to 1 in 100 people): high levels of liver components in the blood (plasma), loss of appetite, nausea, vomiting, chills, dizziness, and headache.

Rare(may affect up to 1 in 1000 people): low or high blood pressure, difficulty breathing, rapid heart rate (tachycardia). Hypersensitivity reactions (which can cause symptoms such as swelling, fever, drop in blood pressure, skin rash, hives, redness, headache). Feelings of cold and heat. Paleness. Lips and skin with bluish discoloration (due to lack of oxygen in the blood). Pain in the neck, back, bones, chest, and lumbar region.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of SMOFKABIVEN PERIPHERAL

Keep this medicine out of the sight and reach of children.

Keep in the outer bag. Do not store above 25°C. Do not freeze.

Do not use this medicine after the expiry date which is stated on the bag and carton.

The expiry date is the last day of the month stated.

6. Container Content and Additional Information

The other ingredients are: glycerol, purified egg phospholipids, all-rac-α-tocopherol, sodium hydroxide (pH adjustment), sodium oleate, acetic acid (pH adjustment), and water for injectables

Appearance of the Product and Container Content

The glucose and amino acid solutions are clear, colorless or slightly yellow, and particle-free. The lipid emulsion is white and homogeneous.

Container Sizes:

1 x 1206 ml, 4 x 1206 ml

1 x 1448 ml, 4 x 1448 ml

1 x 1904 ml, 4 x 1904 ml

Marketing Authorization Holder and Manufacturer

Holder:

Fresenius Kabi España S.A.U.

C/ Marina 16-18,

08005 Barcelona (Spain)

Manufacturer:

Fresenius Kabi AB, SE-751 74 Uppsala, Sweden

Fresenius Kabi Austria GmbH, AT-8055 Graz, Austria

For any information about this product, please contact the marketing authorization holder.

Date of the Last Revision of this Leaflet: March 2023

-----------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Special Warnings and Precautions for Use

To avoid the risks associated with too rapid infusion rates, it is recommended to use continuous and well-controlled infusion, if possible using an infusion pump.

Since the use of a peripheral vein is associated with a high risk of infection, strict aseptic precautions should be taken to avoid any contamination during catheter insertion and handling.

Serum glucose, electrolytes, and osmolarity, as well as fluid balance, acid-base balance, and liver enzyme tests, should be monitored.

Upon any sign or symptom of anaphylactic reaction (such as fever, shivering, skin rash, or dyspnea), the infusion should be interrupted immediately.

SmofKabiven Periférico should not be administered simultaneously with blood in the same infusion equipment due to the risk of pseudoagglutination.

Thrombophlebitis may occur if peripheral veins are used for infusion. The catheter insertion site should be evaluated daily for local symptoms of thrombophlebitis.

Method of Administration

Intravenous, infusion in a peripheral or central vein.

To provide complete parenteral nutrition, trace elements, vitamins, and possibly electrolytes should be added to SmofKabiven Periférico (taking into account the electrolytes already present in SmofKabiven Periférico), according to the patient's needs.

Posology

Adults

Dosage: The dose range of 20-40 ml SmofKabiven periférico/kg body weight/day will provide 0.6-1.3 g of amino acids/kg body weight/day (corresponding to 0.10-0.20 g nitrogen/kg body weight/day) and 14-28 kcal/kg body weight/day of total energy (11-22 kcal/kg body weight/day of non-protein energy).

Infusion Rate

The maximum infusion rate for glucose is 0.25 g/kg body weight/h, for amino acids 0.1 g/kg body weight/h, and for lipids 0.15 g/kg body weight/h.

The infusion rate should not exceed 3.0 ml/kg body weight/hour (corresponding to 0.10 g of amino acids, 0.21 g of glucose, and 0.08 g of lipids/kg body weight/h). The recommended infusion period is 14-24 hours.

Maximum Daily Dose: The maximum daily dose varies with the patient's clinical situation and may even change from day to day. The recommended maximum daily dose is 40 ml/kg body weight/day.

Pediatric Population

Children (2-11 years)

Dosage:

The dose of up to 40 ml/kg body weight/day should be adjusted regularly according to the pediatric patient's requirements, which vary more than in adult patients.

Infusion Rate:

The maximum infusion rate is 3.0 ml/kg body weight/h (corresponding to 0.10 g of amino acids/kg/h, 0.21 g of glucose/kg/h, and 0.08 g of lipids/kg/h).

The recommended infusion period is 12-24 hours.

If the recommended maximum daily dose is used, the dose should be infused over a period of at least 13 hours to not exceed the recommended maximum infusion rate, except in particular cases.

Maximum Daily Dose: The maximum daily dose varies with the patient's clinical condition and may even change from day to day. The maximum daily dose is 40 ml/kg body weight/day.

Adolescents (12-16/18 years)

SmofKabiven Periférico can be used in adolescents in the same way as in adults.

Precautions for Use

Do not use the container if it is damaged.

Use only if the amino acid and glucose solutions are clear, colorless or slightly yellow, and if the lipid emulsion is white and homogeneous. The contents of the three separate chambers should be mixed before use and before making any additions through the additive port.

After opening the peel-type seals, the bag should be inverted several times to ensure a homogeneous mixture, which does not show evidence of phase separation.

For single use. Any leftover mixture should be discarded after infusion.

Compatibility

There are compatibility data with defined quantities of the products with the trade names Dipeptiven 200 mg/ml, Supliven, Glycophos 216 mg/ml, Vitalipid Adult/Infant, and Soluvit lyophilized and generic electrolytes in defined concentrations. When adding electrolytes, the quantities already present in the bag should be taken into account to meet the patient's clinical needs. The generated data support additions to the activated bag according to the summary table shown below.

Compatibility range established for 7 days, i.e., 6 days of storage at 2-8°C followed by 24 hours at 20-25°C.

1 includes the quantities of all products.

Note: This table is intended to indicate compatibility. It is not a dosage guide. In the case of trade-name products, before prescribing, consult the approved product information.

There are data on compatibility with other additives and the shelf life of the different mixtures, available upon request.

Additions should be made aseptically.

Validity Period after Mixing the Bag Chambers

The physical and chemical stability of the mixed three-chamber bag has been demonstrated for 48 hours at 20-25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, the storage time until use and the conditions prior to use are the responsibility of the user and should not normally exceed 24 hours at 2-8°C, unless the mixture was made under controlled and validated aseptic conditions.

Validity Period after Mixing with Additives

Physical-chemical stability has been demonstrated for the mixed three-chamber bag with additives for up to 7 days, i.e., 6 days at 2-8°C followed by 24 hours at 20-25°C, including the duration of administration. From a microbiological point of view, the product should be used immediately after making the additions. If not used immediately, the storage time until use and the conditions prior to use are the responsibility of the user. The storage time should not normally exceed 24 hours at 2-8°C, unless the mixture was made under controlled and validated aseptic conditions.

Instructions for the Use of SmofKabiven Periférico

The Bag

1. Notches on the overbag
2. Hanger
3. Hanger ring
4. Peel-type seal
5. Port without outlet (only used during manufacturing)
6. Additive port
7. Infusion port
8. Oxygen absorber

1. Removal of the overbag

• To remove the overbag, hold it in a horizontal position and tear along the notch towards the ports along the top edge (A).
• Then, simply tear along the container; separate the overbag and discard it along with the oxygen absorber (B).

1. Mixing

• Place the bag on a flat surface.
• Roll the bag firmly from the hanger part towards the ports, first with the right hand and then exerting constant pressure with the left hand until the vertical seal breaks. The peel-type seal opens due to the fluid pressure. The peel-type seals can also be opened before removing the overbag.

Note:The liquids mix easily even if the horizontal seal remains closed.

• Mix the contents of the three chambers by inverting the bag three times until the components are completely mixed.

1. Final Preparation:

• Place the bag back on a flat surface. Just before injecting additives, break the white additive port by the arrow mark (A).

Note:The additive port membrane is sterile.

• Hold the base of the additive port. Insert the needle, inject the additives (of known compatibility) through the center of the injection point (B).
• Mix thoroughly between each addition, inverting the bags three times. Use syringes with 18-23 gauge needles and a maximum length of 40 mm.

• Just before inserting the infusion equipment, break the blue infusion port by the arrow mark (A).

Note:The infusion port membrane is sterile.

• Use non-vented infusion equipment or close the air inlet of the vented equipment.
• Hold the base of the infusion port.
• Insert the needle through the infusion port. The spike will be fully inserted to ensure its retention.

Note:The inner part of the infusion port is sterile.

1. Hanging the Bag

• Hang the bag by the ring under the hanger.